Literature DB >> 29404753

Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Xu-Feng Zhang1,2, Eliza W Beal2, Jeffery Chakedis2, Qinyu Chen2, Yi Lv1, Cecilia G Ethun3, Ahmed Salem4, Sharon M Weber4, Thuy Tran5, George Poultsides5, Andre Y Son6, Ioannis Hatzaras6, Linda Jin7, Ryan C Fields7, Stefan Buettner8, Charles Scoggins9, Robert C G Martin9, Chelsea A Isom10, Kamron Idrees10, Harveshp D Mogal11, Perry Shen11, Shishir K Maithel3, Carl R Schmidt2, Timothy M Pawlik12,13.   

Abstract

BACKGROUND: Time to tumor recurrence may be associated with outcomes following resection of hepatobiliary cancers. The objective of the current study was to investigate risk factors and prognosis among patients with early versus late recurrence of hilar cholangiocarcinoma (HCCA) after curative-intent resection.
METHODS: A total of 225 patients who underwent curative-intent resection for HCCA were identified from 10 academic centers in the USA. Data on clinicopathologic characteristics, pre-, intra-, and postoperative details and overall survival (OS) were analyzed. The slope of the curves identified by linear regression was used to categorize recurrences as early versus late.
RESULTS: With a median follow-up of 18.0 months, 99 (44.0%) patients experienced a tumor recurrence. According to the slope of the curves identified by linear regression, the functions of the two straight lines were y = -0.465x + 16.99 and y = -0.12x + 7.16. The intercept value of the two lines was 28.5 months, and therefore, 30 months (2.5 years) was defined as the cutoff to differentiate early from late recurrence. Among 99 patients who experienced recurrence, the majority (n = 80, 80.8%) occurred within the first 2.5 years (early recurrence), while 19.2% of recurrences occurred beyond 2.5 years (late recurrence). Early recurrence was more likely present as distant disease (75.1% vs. 31.6%, p = 0.001) and was associated with a worse OS (Median OS, early 21.5 vs. late 50.4 months, p < 0.001). On multivariable analysis, poor tumor differentiation (HR 10.3, p = 0.021), microvascular invasion (HR 3.3, p = 0.037), perineural invasion (HR 3.9, p = 0.029), lymph node metastases (HR 5.0, p = 0.004), and microscopic positive margin (HR 3.5, p = 0.046) were independent risk factors associated with early recurrence.
CONCLUSIONS: Early recurrence of HCCA after curative resection was common (~35.6%). Early recurrence was strongly associated with aggressive tumor characteristics, increased risk of distant metastatic recurrence and a worse long-term survival.

Entities:  

Mesh:

Year:  2018        PMID: 29404753     DOI: 10.1007/s00268-018-4530-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  43 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 2.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

3.  Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.

Authors:  A Kobayashi; S Miwa; T Nakata; S Miyagawa
Journal:  Br J Surg       Date:  2010-01       Impact factor: 6.939

4.  Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Yi Lv; Fabio Bagante; Luca Aldrighetti; George A Poultsides; Todd W Bauer; Ryan C Fields; Shishir Kumar Maithel; Hugo P Marques; Matthew Weiss; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-07-20       Impact factor: 3.452

5.  Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV.

Authors:  Q-B Cheng; B Yi; J-H Wang; X-Q Jiang; X-J Luo; C Liu; R-Z Ran; P-N Yan; B-H Zhang
Journal:  Eur J Surg Oncol       Date:  2012-09-16       Impact factor: 4.424

Review 6.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma.

Authors:  Sander Dinant; Michael F Gerhards; Olivier R C Busch; Hugo Obertop; Dirk J Gouma; Thomas M Van Gulik
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 9.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

10.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Authors:  William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

View more
  16 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  [Influence of molecular pathology on oncological surgery of liver and bile duct tumors].

Authors:  Mazen A Juratli; Benjamin Struecker; Shadi Katou; M Haluk Morguel; Andreas Pascher
Journal:  Chirurg       Date:  2021-09-14       Impact factor: 0.955

3.  Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?

Authors:  Andrew J Sinnamon; Anthony C Wood; Megan A Satyadi; Catherine V Levitt; Olivia Hardy; Mintallah Haider; Richard D Kim; Daniel A Anaya; Jason W Denbo
Journal:  J Gastrointest Oncol       Date:  2022-06

4.  Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-08-03       Impact factor: 3.452

Review 5.  Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy.

Authors:  Michael K Turgeon; Shishir K Maithel
Journal:  Chin Clin Oncol       Date:  2019-09-02

Review 6.  Resection for Klatskin tumors: technical complexities and results.

Authors:  Ivan Capobianco; Jens Rolinger; Silvio Nadalin
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-18

7.  Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma.

Authors:  Teiichi Sugiura; Katsuhiko Uesaka; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Katsuhisa Ohgi; Hirofumi Asakura; Akiko Todaka; Akira Fukutomi
Journal:  Ann Gastroenterol Surg       Date:  2020-05-15

8.  Pattern of the First Recurrence Has No Impact on Long-Term Survival after Curative Intent Surgery for Perihilar Cholangiocarcinomas.

Authors:  Madalina Maria Blaga; Vladislav Brasoveanu; Cezar Stroescu; Mihnea Ionescu; Irinel Popescu; Traian Dumitrascu
Journal:  Gastroenterol Res Pract       Date:  2018-08-09       Impact factor: 2.260

Review 9.  Surgery for cholangiocarcinoma.

Authors:  Umberto Cillo; Constantino Fondevila; Matteo Donadon; Enrico Gringeri; Federico Mocchegiani; Hans J Schlitt; Jan N M Ijzermans; Marco Vivarelli; Krzysztof Zieniewicz; Steven W M Olde Damink; Bas Groot Koerkamp
Journal:  Liver Int       Date:  2019-05       Impact factor: 5.828

Review 10.  The value of lymphadenectomy in surgical resection of perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Lei Liang; Chao Li; Ming-Da Wang; Hao Xing; Yong-Kang Diao; Hang-Dong Jia; Wan Yee Lau; Timothy M Pawlik; Cheng-Wu Zhang; Feng Shen; Dong-Sheng Huang; Tian Yang
Journal:  Int J Clin Oncol       Date:  2021-06-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.